A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression.-Reference-Cited by-同舟云学术

A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression.

Published:1983-06 Issue:S3 Volume:15 Page:433S-438S
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:British Journal of Clinical Pharmacology

Author:

Itil TM,Shrivastava RK,Mukherjee S,Coleman BS,Michael ST

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.1983.tb02134.x/fullpdf

Reference18 articles.

1. Assessment of depression: the depression inventory;BECK;Psychopharmacology,1974

2. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor;CLAASSEN;Br. J. Pharmac.,1977

3. CLAASSEN , V. POST , L.C. 1974 Compilations of pharmacological properties, pharmacokinetics and metabolite patterns of DU 23000 Duphar Report no. 56648/71/74

4. Abnormalities of indolamines in affective disorders;COPPEN;Arch, gen Psychiat.,1972

5. DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS 1980 3rd ed Am. Psychiat. Ass. , 202-222

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis;BMJ Mental Health;2024-01

2. Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain;PLOS ONE;2020-12-16

3. Staging Treatment Intensity and Defining Resistant Depression;The Journal of Clinical Psychiatry;2019-06-04

4. Katakam and co-workers have not shown SSRIs to be harmful and ineffective and should stop claiming that they have;Acta Neuropsychiatrica;2018-07-19

5. Great boast, small roast on effects of selective serotonin reuptake inhibitors: response to a critique of our systematic review;Acta Neuropsychiatrica;2018-02-21